NSE · SUVEN
Suven Life Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4 Cr with net profit ₹-16 Cr — a -451.54% net margin, versus -1313.12% the period before.
Shareholding
As of 2026-08-31
- Promoter65.47%
- Public31.32%
- FII0.48%
- DII2.73%
66,647 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.25× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #48 of 541 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹4,06,557 Cr | 30.6 | 4.24 | 13.32% | 32.43% |
| Eternal Limited | ₹3,12,189 Cr | 718.89 | 10.05 | 1.18% | 0.64% |
| Vedanta Aluminium Metal Limited | ₹1,64,921 Cr | 13.73 | 421.6 | 49.39% | 21.35% |
| BSE Limited | ₹1,38,028 Cr | 48.75 | 20.68 | 37.42% | 52.03% |
| One 97 Communications Ltd. | ₹1,15,971 Cr | 142.89 | 7.23 | 4.55% | 7.25% |
| GAIL (India) Ltd. | ₹1,14,157 Cr | 11.56 | 1.28 | 8.51% | 6.67% |
| GMR Airports Limited | ₹1,03,457 Cr | 171.89 | 0 | -10.6% | 3.07% |
| Meesho Limited | ₹1,00,426 Cr | — | 22.81 | -28.13% | -8.68% |
| Mazagon Dock Shipbuilders Ltd. | ₹94,351 Cr | 33.01 | 9.66 | 26.48% | 21.45% |
| Multi Commodity Exchange of India Ltd. | ₹83,535 Cr | 54.18 | 29.32 | 46.75% | 58.61% |
| Suven Life Sciences Ltd.(this company) | ₹10,047 Cr | — | 14.64 | -46.73% | -3995.92% |
AI analysis
AI-generated · google/gemini-2.5-flashSuven Life Sciences Ltd. is listed with a market capitalization of Rs 9565 Cr. The company reported a revenue of Rs 17.55 Cr with a profit margin of -3881.32%. Its 52-week high was Rs 371 and its 52-week low was Rs 124.11.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is substantial at 70.0777% as of June 30, 2026.
- +There are no reported promoter pledges.
Negatives
- −The company reported a negative profit margin of -3881.32%.
- −Revenue declined by -43.1%.
- −Return on Equity (ROE) is significantly negative at -46.73%.
- −Return on Capital Employed (ROCE) is significantly negative at -45.4184%.
- −The company is under LT-ASM (Long Term Additional Surveillance Measure) Stage 1.
Financial Performance
The company's annual revenue declined by -43.1% to Rs 17.55 Cr. Quarterly revenue for March 2026 was Rs 1.52 Cr, following Rs 2.81 Cr in December 2025 and Rs 0.92 Cr in September 2025. Net profit for March 2026 was -Rs 45.6 Cr, which was an improvement from -Rs 101.92 Cr in December 2025.
Profitability & Returns
Suven Life Sciences Ltd. reported a negative profit margin of -3881.32%. The Return on Equity (ROE) was -46.73%, and the Return on Capital Employed (ROCE) was -45.4184%. Quarterly EBITDA has been consistently negative, with -Rs 45.44 Cr in March 2026 and -Rs 101.92 Cr in December 2025.
Balance Sheet
The company maintains a debt-to-equity ratio of 0, indicating no debt. The book value per share stands at Rs 29.74. While debt-free, the negative profitability ratios suggest challenges in generating returns from existing capital.
Ownership & Pledges
As of June 30, 2026, promoters held 70.0777% of the shares, with public holding at 26.4284%. Institutional holding, including DIIs and FIIs, was 3.4939%. There were no promoter pledges reported, indicating no shares were encumbered by the promoters.
Regulatory & Surveillance
Suven Life Sciences Ltd. is currently under LT-ASM (Long Term Additional Surveillance Measure) Stage 1, a regulatory measure. This indicates the exchange has identified parameters requiring closer monitoring.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Aug 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.